Phase 2 Depression and Anxiety Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 99 years, of any gender
- People who have been staying in an intensive care unit (ICU) for 6 or more days at the time of screening
- People showing moderate to severe signs of depression, based on a standard questionnaire score of 10 or higher at the time of screening
- People who are able to understand and agree to take part in the study (provide informed consent)
Who may not be able to join:
- People with a history of psychosis or hallucinations, based on a review of their medical records and an interview during screening
- People with a history of a heart condition involving a prolonged QT interval (an abnormal heart rhythm pattern)
- People with a history of dementia
- People who had a diagnosis of major depressive disorder before their current ICU stay
- People with a history of certain mental health diagnoses, including dissociative disorder, primary psychotic disorder, mania with psychosis, pervasive developmental disorder, cognitive disorder, or anorexia nervosa
- People with a known allergy to ketamine or diphenhydramine
- People with a history of raised pressure in the brain or the eyes, or a condition called hypertensive hydrocephalus
- People whose vital signs are unstable at the time of screening — for example, blood oxygen level, blood pressure, heart rate, or breathing rate that falls outside safe ranges
- People who decline to take part or are unable to give informed consent
- People who are pregnant, within 2 months after giving birth, or currently breastfeeding
- People with a known mass or blood vessel abnormality in the brain
- People whose mental state at the time of screening prevents them from giving informed consent
- People whose body weight is below 45 kg or above 115 kg
- People currently experiencing active psychosis
- People currently taking certain medications that affect a specific brain receptor system, including lamotrigine, acamprosate, memantine, riluzole, or lithium
- People currently taking aminophylline or theophylline
- People currently going through withdrawal from a substance, or who have used hallucinogens — including cannabis — in the past month, as determined by interview and a urine test
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ivan A Huespe, MD, Hospital Italiano de Buenos Aires
Phone: +5493425382554
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in PHQ-9 Score from Baseline to Day 30 Post-Last Infusion; Incidence of Safety Events During and After Ketamine Infusion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.